Skip to main content

Mental Retardation

3
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
2
risperidonePhase 31 trial
sertralinePhase 31 trial
Healthy Lifestyles CurriculumN/A1 trial
Active Trials
NCT00597948Completed131Est. Mar 2010
NCT00065273Completed50Est. Jun 2001
NCT00491478Unknown
Spine BioPharma
Spine BioPharmaNY - New York
1 program
1
Stem CellPhase 11 trial
Active Trials
NCT02245724Withdrawn0Est. Sep 2016
CENTOGENE
CENTOGENEGermany - Rostock
1 program
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)N/A1 trial
Active Trials
NCT02298686Withdrawn0Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesrisperidone
Human BioSciencessertraline
Spine BioPharmaStem Cell
CENTOGENEBiomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)
Human BioSciencesHealthy Lifestyles Curriculum

Clinical Trials (5)

Total enrollment: 181 patients across 5 trials

NCT00065273Human BioSciencesrisperidone

Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

Start: Jul 1998Est. completion: Jun 200150 patients
Phase 3Completed
NCT00491478Human BioSciencessertraline

Repetitive Behavior Disorders in People With Severe Mental Retardation

Start: Sep 1992
Phase 3Unknown
NCT02245724Spine BioPharmaStem Cell

Stem Cell Therapy in Mental Retardation

Start: Sep 2011Est. completion: Sep 20160
Phase 1Withdrawn
NCT02298686CENTOGENEBiomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
NCT00597948Human BioSciencesHealthy Lifestyles Curriculum

Healthy Lifestyles for People With Intellectual Disabilities

Start: Apr 2007Est. completion: Mar 2010131 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.